Market News AIOpen the app

J.P. Morgan increased its target price for Kura Oncology to $32, keeping a buy rating.

OpinionRead the original at moomoo.com
Good for KURA

J.P. Morgan raised its target from $30 to $32 and kept its bullish rating.

KURA · Kura Oncology

AI read · Good for KURA

The AI's read

This is an outside analyst's opinion, not a change in Kura's business. The higher target and continued bullish rating favor its shares, but the story reports no new company results.

Get alerts for KURA

Follow Kura Oncology (KURA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for KURA
Free on the App Store and Google Play, or on the web.